About cCARE’s cancer research
cCARE is proud to offer numerous institutional-grade clinical trials for cancer patients. Clinical trials assess new drug or treatment effectiveness and provide cancer patients with the newest – and possibly most effective – forms of treatment.
Cancer clinical trials are divided into three different phases. Phase I trials assess the safety of a drug or treatment; phase II trials quantify how effective the treatment is while phase III compares the trial to the best existing cancer treatment.
The decision to participate in a cancer clinical trial should be made early in the diagnosis stage because once treatment begins, patients may not be eligible to participate in certain clinical trials. Benefits of participating in cancer clinical trials include access to the newest treatment and medicine designed to fight your particular type of cancer as well as being monitored closely throughout the treatment process.
Although clinical trials provide many benefits, patients must consider the risks as well. Participants may experience unforeseen side effects, the treatment may just not work as well as previous methods and health insurance coverage may not extend to participating in a trial. Speak with your oncologist about whether or not a clinical trial is right for your specific case.
Open cancer clinical trials at cCARE
Below is a list of cancer clinical trials currently open at cCARE. If you have any questions about our San Diego trials, please call us at 760-452-3909 or email our Clinical Research Manager Christina Spencer, BS, CCRP, at [email protected].
For Fresno trials, please call 559-326-1222, option 1, extension 4008.
Research contact centers
Director of Research: Christina Spencer, BS, CCRP
Phone: 760-452-3909 ext. 1311
cCARE Encinitas
Research Coordinator: Dante Pasiliao
Phone: 760-452-3909 ext. 1312
cCARE Fresno
Research Coordinator: Helena Tubb
Phone: 559-326-1222 ext. 2171
cCARE San Marcos
Research Coordinator: Negia Gamboa
Phone: 760-747-8935 ext. 508
Research Coordinator: Kimberly Tang
Phone: 760-747-8935 ext. 515
San Diego cancer clinical trials – (jump to Fresno clinical trials)
Advanced Tumor Clinical Trial: KRAS G12C Mutation
Title: Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 in patients with advanced solid tumors that have a KRAS G12C mutation.
Learn More About This Cancer Study
Lymphoma Clinical Trial: Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN-CLL-314)
Title: A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN-CLL-314)
The purpose of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL. Participants may or may not have already had treatment for their cancer. Participation could last up to six years.
Learn More About This Cancer Study
Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer Clinical Trial: Covalent Menin Inhibitor BMF-219
Title: Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer
A Phase 1/1b dose finding study to determine the OBD(s) and RP2D(s) of BMF-219, a covalent menin inhibitor small molecule, in subjects with KRAS mutated unresectable, locally advanced, or metastatic NSCLC (Cohort 1), PDAC (Cohort 2), and CRC (Cohort 3).
Learn More About This Cancer Study
Solid Tumors, Advanced: Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
Title: Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
This clinical trial is evaluating a drug called BT5528 alone and in combination with nivolumab in participants with advanced solid tumors that are identified as positive for EphA2 expression.
Learn More About This Cancer Study
Solid Tumors Clinical Trial: Advanced
Title: A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of XTX101 Monotherapy and XTX101 and Pembrolizumab Combination Therapy in Patients With Advanced Solid Tumors
This is a first-in-human, Phase 1/2, multicenter, open-label study designed to evaluate the safety and tolerability of XTX101 as monotherapy and XTX101 and pembrolizumab combination therapy in patients with advanced solid tumors.
Learn More About This Cancer Study
Solid Tumors Clinical Trial: Advanced
Title: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC61in Subjects With Advanced Solid Tumors
This is a Phase 1, open-label, multicenter, single-arm, dose escalation study, designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of single-agent ASC61(an orally bioavailable small-molecule inhibitor of PD-L1) in subjects with advanced solid tumors for whom no standard therapy is available.
Learn More About This Cancer Study
Solid Tumors Clinical Trial: Advanced
Title: Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC. (SCLC)
This is a Phase 1b/2, single-arm, open-label, dose-escalation study including 2 stages:
Phase 1b: Dose-Escalation Stage (Single-Dose and Consecutive-Dose Periods)
Phase 2: recommended Phase 2 dose (RP2D) of chiauranib will be given to all patients enrolled in this phase once daily for 28-day cycles continuously with no interruption between cycles.
Learn More About This Cancer Study
Solid Tumors Clinical Trial: Advanced
Title: Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors
The purpose of this study is to assess the safety and tolerability of BGB-A445 alone and in combination with tislelizumab in participants with advanced solid tumors; and to determine the maximum tolerated dose(s) (MTD) or maximum administered dose(s) (MAD) and recommended Phase 2 doses (RP2D) of BGB-A445 alone and in combination with tislelizumab.
Learn More About This Cancer Study
Solid Tumors Clinical Trial: Metastatic
Title: Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors
This trial will find out whether brentuximab vedotin and pembrolizumab work together to treat different types of cancer. There will be several different types of cancer studied in the trial. The cancer must have spread to other parts of the body (metastatic) and must have gotten worse (progressed) after being treated with a PD-1 inhibitor treatment.
The study will also find out what side effects occur (a side effect is anything the treatment does besides treat cancer). This is a multi-cohort study.
Learn More About This Cancer Study
Zimberelimab and Domvanalimab in Combination With Chemotherapy
Title: Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer (STAR-121)
The primary objective of this study is to compare the effect of zimberelimab (ZIM) and domvanalimab (DOM) in combination with chemotherapy relative to pembrolizumab (PEMBRO) in combination with chemotherapy on progression-free survival (PFS) and overall survival (OS) in patients with untreated metastatic non-small cell lung cancer with no actionable genomic alteration.
Learn More About This Cancer Study
Advanced Metastatic Breast Cancer: ARV-471 (PF-07850327)
Title: A Study to Learn About a New Medicine Called ARV-471 (PF-07850327) in People Who Have Advanced Metastatic Breast Cancer. (VERITAC-2)
A study to learn about a new medicine called ARV-471 (PF-07850327) in people who have advanced metastatic breast cancer.
Learn More About This Cancer Study
Metastatic Colorectal Cancer (INTRINSIC)
Title: A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
This open-label, exploratory study is designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or combinations, in participants with metastatic colorectal cancer (mCRC) whose tumors are biomarker positive as per treatment arm-specific definition. Eligible participants with mCRC will be enrolled into specific treatment arms based on their biomarker assay results.
Learn More About This Cancer Study
Advanced Solid Tumors: PT-112 Injection
Title: A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts
This is a Phase 1/2, open-label, multi-center, non-randomized, dose-escalation study to be conducted in two parts: the Dose Escalation Phase and the Dose Expansion Phase. The Dose Escalation Phase will determine the Maximum Tolerated Dose (MTD) and recommended Phase 2 dose(s) (RP2D) of PT-112 Injection and evaluate its safety and tolerability, and PK (pharmacokinetics). The Dose Escalation Phase is no longer enrolling. The Dose Expansion Phase has two cohorts: one cohort for the study of PT-112 in patients with thymoma and thymic carcinoma (Cohort A), and one cohort for the study of PT-112 in metastatic castrate-resistant prostate cancer (mCRPC) (Cohort D).
Learn More About This Cancer Study
JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors
Title: A Phase 1, first-in-human, open-label, multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors
This Phase 1 first-in-human study will investigate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary antitumor activity of JZP898 monotherapy as well as JZP898 in combination with pembrolizumab in adult participants with advanced or metastatic solid tumors.
Learn More About This Cancer Study
DB-1311 in Advanced/Metastatic Solid Tumors
Title: A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1311 in Subjects with Advanced/Metastatic Solid Tumors
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311 in subjects with advanced solid tumors.
Learn More About This Cancer Study
A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer
Title: A Phase 1/2 Open-Label, Dose-Escalation and Cohort Expansion Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARV-766 Monotherapy and in Combination With Abiraterone in Patients With Metastatic Prostate Cancer
A Phase 1/2 study to evaluate the safety and efficacy of ARV-766 given by mouth alone or in combination with abiraterone in men with metastatic prostate cancer.
Learn More About This Cancer Study
A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma
Title: A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
This phase 3 randomized, open-label multicenter trial will compare the efficacy, safety and the impact on health-related quality of life (HR-QoL) of SPd versus EloPd in pomalidomide-naïve patients with MM who have received 1 to 4 prior anti-MM regimens and been treated with an immunomodulatory imide drug (IMiD), proteasome inhibitor (PI) and an anti-CD38 monoclonal antibody (mAb).
Learn More About This Cancer Study
Fresno cancer clinical trials – (jump to San Diego clinical trials)
Advanced Unresectable or Metastatic Solid Malignancy Trial: Evaluating Targeted Therapies
Title: A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response (MyTACTIC)
This is a Phase II, multicenter, non-randomized, open-label, multi-arm study designed to evaluate the safety and efficacy of targeted therapies as single agents or in rational, specified combinations in participants with advanced unresectable or metastatic solid tumors determined to harbor specific biomarkers.
Breast Cancer Clinical Trial: HER2-Positive at High Risk of Recurrence Following Preoperative Therapy (Astefania)
Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
This is a Phase III, two-arm, randomized, double-blind placebo-controlled study in participants with HER2-positive primary breast cancer who have received preoperative chemotherapy and HER2-directed therapy, including trastuzumab followed by surgery, with a finding of residual invasive disease in the breast and/or axillary lymph nodes.
Learn More About This Cancer Study
Head and Neck Squamous Cell Carcinoma Clinical Trial: Advanced, Recurrent or Metastatic
Title: A Phase 1b/2 Study of the Combination of Pepinemab and Pembrolizumab in Patients With Advanced, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
The purpose of the study is to evaluate the safety and tolerability of pepinemab in combination with pembrolizumab and determine a recommended Phase 2 dose (RP2D) in patients with advanced, recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).
Learn More About This Cancer Study
Metastatic Breast Cancer: Advanced ARV-471
Title: A Study to Learn About a New Medicine Called ARV-471 (PF-07850327) in People Who Have Advanced Metastatic Breast Cancer. (VERITAC-2)
A study to learn about a new medicine called ARV-471 (PF-07850327) in people who have advanced metastatic breast cancer.
Learn More About This Cancer Study
Myelofibrosis Clinical Trial: Compare the Efficacy of Drug Combinations
Title: To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis
The purpose of the study is to compare the efficacy of parsaclisib when combined with ruxolitinb versus placebo combined with ruxolitinib in participants with myelofibrosis.
Learn More About This Cancer Study
Myelofibrosis Clinical Trial: Myelofibrosis Participants Who Have Suboptimal Response to Ruxolitinib
Title: To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib
The purpose of the study is to compare the efficacy and safety of parsaclisib when combined with ruxolitinb versus placebo combined with ruxolitinib in participants with myelofibrosis who have suboptimal response while receiving ruxolitinib monotherapy.
Learn More About This Cancer Study
Phase 3 Study: Polycythemia Vera
Title: A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera (VERIFY)
The study is designed to evaluate the safety and efficacy of rusfertide in subjects with polycythemia vera (PV) in maintaining hematocrit control and in improving symptoms of PV.
Learn More About This Cancer Study
realMIND: Relapsed or Refractory
Title: realMIND: Observational Study of Patients With Relapsed or Refractory DLBCL Starting Second- or Third-line Therapy (realMIND)
REAL-MIND: Prospective multicenter observational study of patients with relapsed or refractory diffuse large B-cell lymphoma starting second- or third-line therapy and not receiving autologous stem cell transplant
Learn More About This Cancer Study
Solid Tumor Clinical Trial: Adult
Title: Study to Evaluate D-1553 in Subjects with Solid Tumors
This is a phase 1/2, open label study of D-1553 single agent and combination treatment to assess the safety and tolerability, identify the MTD and RP2D, evaluate the PK properties and antitumor activities in subjects with advanced or metastatic solid tumor with KRasG12C mutation.
Learn More About This Cancer Study
Solid Tumor Clinical Trial: Metastatic
Title: A Phase 2 Study of Brentuximab Vedotin in Combination With Pembrolizumab in Subjects With Metastatic Solid Malignancies After Progression on Prior PD-1 Inhibitor Treatment
This trial will find out whether brentuximab vedotin and pembrolizumab work together to treat different types of cancer. There will be several different types of cancer studied in the trial. The cancer must have spread to other parts of the body (metastatic) and must have gotten worse (progressed) after being treated with a PD-1 inhibitor treatment. The study will also find out what side effects occur. A side effect is anything the treatment does besides treat cancer.
Learn More About This Cancer Study
Solid Tumor Clinical Trial: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics
Title: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC61in Subjects With Advanced Solid Tumors
This is a Phase 1, open-label, multicenter, single-arm, dose escalation study, designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of single-agent ASC61(an orally bioavailable small-molecule inhibitor of PD-L1) in subjects with advanced solid tumors for whom no standard therapy is available.